INTRODUCTION
A contaminated wound is one of the most common pathways for internal deposition of actinides in nuclear workers. More than two thousand reports on contamination incidents involving skin injury have been published in scientific literature (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . A contaminated wound may potentially result in high radiation doses to the whole body and/or to particular organs or tissues. In order to prevent the potential health effects and reduce the systemic deposition, contaminated wounds are frequently treated by localized tissue excision and, if necessary, by administering chelation therapy.
The National Council on Radiation Protection and Measurements (NCRP) developed the contaminated wound model (19) to provide a mechanistic basis for predicting retention of radionuclides within the wound site, clearance to blood and, ultimately, urinary excretion. A schematic of the generic wound model adopted from NCRP Publication 156 (19) is depicted in Figure 1 . In this biokinetic model, the wound site is represented by five compartments: (1) soluble, (2) fragment, (3) colloid and intermediate state (CIS), (4) particles, aggregates and bound state (PABS) and (5) trapped particles and aggregates (TPA). From the wound site, radionuclides are cleared to blood and lymph nodes. Material transfer between the compartments is assumed to follow first-order kinetics (19) . Based on physical and chemical properties, the deposited radioactive material can be initially in soluble, colloidal, particulate or fragment form. Soluble material is further categorized as weak, moderate, strong or avid based on wound retention times observed in experimental studies. Default sets of transfer rate constants are defined in NCRP Publication 156 for each of the seven material categories (19) . The wound biokinetic model was designed and parameterized using data from experimental animal studies. It is important to test and verify the model predictions against human data for a variety of radioactive materials involved in occupational accidents at nuclear facilities.
The whole-body donation to the United States Transuranium and Uranium Registries (USTUR)-Case 0212-provides a detailed and complete data record of an accidental wound intake of soluble plutonium treated with Ca-DTPA administered intravenously (i.v.). Urine samples were collected and analyzed throughout the treatment period, as well as during the following 3 years. Urine measurements combined with post-mortem radiochemical analyses of key target tissues including the liver, skeleton and wound site were used in this study to test the NCRP wound model and estimate the intake along with the resulting committed dose. An alternative to the NCRP wound model is wound retention represented as a sum of exponential terms, whose coefficients and rates are determined empirically from the data (7, 16, 19) . However, this approach was beyond the scope of the objectives of this paper.
CASE DESCRIPTION
USTUR whole-body donor, Case 0212, worked at a defense nuclear facility over~30 years. The medical and occupational history of this case was previously described elsewhere (20) . According to the worksite's exposure records, this individual had two confirmed intakes during his employment.
The first incident involved skin contamination that also resulted in negligible body deposition of soluble plutonium via inhalation. Two positive urine samples were obtained on the second and third days post-incident. However, plutonium was non-detectable in the following urine samples collected on the 4th and 10th days post-incident. Based on urine data, the worksite personnel estimated the systemic deposition as 0.8 Bq of 239, 240 Pu (20) . Ten years later, the Registrant incurred contaminated wound to the left middle finger while attempting to cut a pipe located on a solvent extraction hood. The plutonium material involved in this accident was identified as nitrate [Pu(NO 3 ) 4 ]. Surface contamination of~170 Bq was measured on the left hand using an alpha survey meter. This was decontaminated tõ 10 Bq. Blood smears were taken after flushing the wound. They measured at~49.4 kBq and 240 Bq for the initial and final samples, respectively.
Initial in vivo measurement at the wound site using a scintillation counter indicated plutonium deposition of~2.2 kBq (Table 1) . This value was later found to be an underestimation. Contaminated tissue was excised 2.5 h after the accident. Measurement of the excised tissue samples showed that~4.5 kBq of plutonium was surgically removed. Residual deposition in the wound was counted at~400 Bq.
Chelation treatment with i.v. injection of Ca-DTPA was initiated immediately following wound excision and continued for 193 days. Ca-DTPA injections were administered twice a week on a regular basis with only two 2-week intervals without treatment during the fourth and fifth months post-accident. Administered Ca-DTPA dosage was 1 g during the first 2 weeks (four treatments) and also 4 months later (two treatments). For all other treatments, the administered amount was 0.5 g. A total of 26.5 g of Ca-DTPA was administered in 47 injections.
The systemic deposition from this wound was previously estimated by the worksite's health physics personnel at 535 Bq of 239 Pu and 4.3 kBq 241 Pu based on urinalysis data (20) . No additional exposure incidents resulting in confirmed deposition of actinides were reported for this worker during the last 14 years of his employment. He died 3 years after retirement, at age 56, from severe pulmonary emphysema.
MATERIALS AND METHODS

Bioassay data
In vivo wound count and urinalysis data from USTUR Case 0212, along with the chronology and dosage of Ca-DTPA treatment, are presented in Figure 2 .
In vivo wound measurements at the worksite were performed with the thin (1-mm) NaI(Tl) detector using a shielding screen with a small aperture. Typically, a detection limit of~3.7 Bq was achieved with a 10-min count (21) . Wound count results for Case 0212 are summarized in Table 1 . The detector was calibrated using 3.26 kBq standard source. The background count rate varied within 1-2 cpm. Plutonium activity in the wound immediately after the tissue excision was measured to be 392 Bq. Three follow-up wound counts were performed during the first 5 months post-accident. Measured plutonium activity in the wound decreased from 592 Bq on Day 7 to 115 Bq on Day 154.
The complete set of urine measurements is provided as Table S1 ( Urine data were based on~24-h sample collection protocol with only two samples collected over 8-h period. The sample volumes were documented for all measurements. Urine samples were analyzed for total α-Pu activity using nuclear track emulsion autoradiography with the minimum detectable activity of 0.83 mBq per 24-h sample (22) . No information on counting uncertainties was available in the worksite records. 
Post-mortem tissue analysis
At autopsy, all major soft tissues and bones were collected for radiochemical analysis for 238 Pu, 239,240 Pu and 241 Am. A complete description of sample collection, dissection, and chemical analysis protocols were described elsewhere (23) (24) (25) . Briefly, the tissue samples were dried at 100°C, dry/wet ashed at 450°C, digested with a mixture of mineral acids, and finally dissolved in hydrochloric acid. Plutonium isotopes 238 Pu, 239,240 Pu were separated from 241 Am and other actinides using combination of ion exchange resins. The isolated plutonium fraction was electroplated and 239,240 Pu and 238 Pu activities were measured with alpha spectrometry. The minimum detectable activity for this method was 1.0 mBq per sample (23) (24) (25) . A total of 90 soft tissue and 174 bone samples were analyzed.
Data analysis
The bioassay data analysis and intake assessment for USTUR Case 0212 were performed using the internal dosimetry software IMBA Professional Plus (26) . IMBA allows estimating the intake from bioassay measurements using the maximum likelihood fitting method.
The NCRP wound model, coupled with the Leggett et al. plutonium systemic model (27) , was applied to 'post-treatment' urine data in order to calculate the best estimate of residual intake, i.e. the amount of plutonium deposited in the wound that was not removed from the system by Ca-DTPA. For data fitting, a log-normal error distribution of urine data with a geometric standard deviation of 1.6 was used, as recommended by the IDEAS Guidelines (28) . Applicability of the NCRP wound model (19) to the bioassay data was examined for default material categories using the empirical multi-exponential retention equation:
where R(t) is the fraction of deposited material retained in the wound at time t (days), and A i is the fraction cleared with the rate of λ i . Recommended parameters for equation (1) are listed in Table 2 .
The chi-square (χ 2 ) test statistic, as implemented in the IMBA Professional Plus 'Statistics' tool, was used to evaluate the goodness-of-fit for each model realization. The fit was considered plausible if the corresponding p-value, a measure of consistency between the sample data and the model predictions (29) , was greater than the predefined level of significance (0.05). Furthermore, using the derived estimates of intake for each category, 239, 240 Pu activities in the liver, skeleton and wound at the time of death were calculated and compared to the measured values.
To determine the 'best' estimate of residual intake and to calculate the corresponding dose, complex intake scenario was defined in IMBA, consisting of independent intake regimes with four different material categories: 'Soluble Strong', 'Soluble Avid', 'Colloid' and 'Particle'. The residual intake was estimated by simultaneously fitting the 'post-treatment' urinary excretion rates and the post-mortem activities in the liver and skeleton. Tables 3 and 4 summarize results of radiochemical  analyses for 239,240 Pu in tissue samples collected at autopsy. Table 3 summarizes   239,240 Pu concentrations measured in soft tissues, and provides information on the 239,240 Pu activity distribution in the total body. Table 4 Pu activity retained in the wound was estimated based on the comparison of measured activities in the skin and muscle of the left and right hands (Table 5) . Radiochemical analyses showed significant difference in 239, 240 Pu concentrations between tissues from the left and right hands. Concentrations in the left hand muscle and skin were a factor of 486 and 64 higher than those in the right hand, respectively. Wound retention was calculated by subtracting the activity measured in the right hand from that of the left hand and adjusting the result for the difference in weights between the right and left hands. Calculations indicated that 14.3 ± 0.3 Bq of 239, 240 Pu was retained in the wound 17 years post-accident.
RESULTS
Plutonium distribution in the body
The post-mortem 239,240 Pu activity in total body was estimated to be 232.0 ± 2.9 Bq. After excluding the wound site, the total systemic 239, 240 Pu activity at the time of death was 217.7 ± 2.9 Bq with 115.1 ± 0.5 Bq in the skeleton, 80.3 ± 2.6 Bq in the liver and 21.2 ± 1.1 Bq in other soft tissues.
Bioassay analysis
To eliminate the effect of DTPA on the individual's normal metabolism, only urine measurements beyond 100 days after the last injection (Day 193 post-intake) were used in bioassay calculations (30, 31) .
Plutonium removed by DTPA
The amount of plutonium excreted in urine during the chelation treatment period and the subsequent 100 days was initially estimated by summing the 239,240 Pu activities in 190 urine samples collected from Day 0 to Day 293 post-accident. This resulted in estimated excretion of 906 Bq with about half of this activity (467 Bq) excreted within the first 17 days, and 90% (817 Bq) excreted within the first 100 days.
To account for excretion on days where urine samples were not collected or analyzed, the sum of measured daily plutonium activities was adjusted by estimating the 239,240 Pu activity that was excreted on the missing days. For the short missing intervals within the first 201 days post-intake (22 days total), estimates of daily excretion rates were derived by interpolating between the previous and subsequent measured values. For longer missing intervals from Day 202 to Day 293, the amount of excreted plutonium was estimated using the average excretion rate of 0.032 ± 0.015 Bq d −1 based on 10 Table 2 . NCRP 156 default parameters for equations describing retention of radionuclides in wounds (1) . urine measurements within this period. The total amount of missing excreted plutonium was estimated to be 10 Bq.
Hence, a total of 916 Bq of plutonium was removed from this individual's body as a result of the Ca-DTPA treatment. 
Evaluating post-treatment urine data
Using IMBA Professional Plus (IPP), urine data from Day 294 through Day 1272 after the wound accident (15 measurements) were fitted to the NCRP wound model for all seven default categories ( Table 2) . Statistics associated with the IPP maximum likelihood fit along with the corresponding estimates of intake are summarized in Table 6 . Model predictions for 239, 240 Pu activities in the liver, skeleton and wound at the time of death were compared with the measured values.
The parameters for six out of seven material categories resulted in acceptable fits to the urine data based on χ 2 statistics. The χ 2 values ranged from 16.1 to 19.4 for 15 data points (degrees of freedom = 14). p-Values ranged from 0.15 to 0.31. IPP maximum likelihood analysis rejected the fit only for the category 'Particle' (p-value < 0.05). The corresponding χ 2 value of 33.2 was higher than the degrees of freedom by a factor of 2.4 indicating that an assumption of 'pure' insoluble (particulate) material cannot explain the urine measurements.
The NCRP wound model recommends using the 'Soluble Strong' category for 239 Pu 4+ in acidic solution. The default parameter set for this category resulted in a credible fit to the post-treatment urine data (χ 2 = 16.3 with p-value of 0.30). However, the model underestimated plutonium retention in the liver and skeleton at the time of death by 18 and 25%, respectively. Moreover, the predicted activity in the wound was underestimated by factor of 100.
The predicted plutonium retention in systemic organs was in best agreement with the measured values for the 'Soluble Avid' category. Default parameters for this type of material predicted retention in the liver and skeleton within 1 and 8%, respectively. However, the wound retention was underestimated by a factor of 33.
The default model recommended for plutonium compounds in colloidal form (category 'Colloid') was in best agreement with the measurement result for wound retention; the predicted wound activity was lower than the measured value by a factor of 5. However, the model overestimated the post-mortem activities in both the liver and skeleton by 22 and 10%, respectively.
The default model parameters for plutonium deposited as 'Fragment' described the post-treatment urine data reasonably well (χ 2 = 16.5) compared to other insoluble categories. However, the model overestimated the post-mortem wound activity by three orders of magnitude.
Given that the model parameters for 'pure' soluble material categories underestimate the wound retention at time of death by orders of magnitude, plutonium material initially deposited in the wound was, most likely, a mixture of different compounds exhibiting both soluble and insoluble behavior.
Estimating intake and dose
The 'best' estimate of residual intake was calculated by simultaneously fitting the 'post-treatment' urinary excretion and post-mortem liver and skeleton retention data. A mixture of soluble strong, soluble avid, colloid and particle compounds was assumed. The results are summarized in Table 7 .
Application of the NCRP wound model default parameter sets for these four categories resulted in an estimated fraction of wound intake that reached the systemic circulation at 288.1 Bq with 224.0 Bq in the 'Soluble Strong' category, and 64.1 Bq as 'Particles'. Essentially, none of this intake was assigned to the 'Soluble Avid' and 'Colloid' categories (<10 −13 Bq). The model predicted plutonium retention in the whole body at the time of death (219.5 Bq) was in good agreement with the measured value. However, the predicted activity in the wound was lower than the measured value by a factor of 3.
The estimated residual intake resulted in a committed effective dose of 134 mSv with 35, 33 and 19% contributed by the liver, bone surfaces and red bone marrow, respectively.
DISCUSSION
The maximum likelihood analysis of bioassay data indicated that the Registrant's internal contamination resulted from a major wound intake of predominantly soluble plutonium with a small, but significant, fraction of insoluble particles. Postmortem tissue analysis results supported this finding. Measurements demonstrated long-term retention of plutonium in the wound. About 6% of the total body activity still remained in the wound 17 years after the accident. This is not consistent with an assumption of pure 'soluble' material initially deposited in the wound. Analysis of autopsy tissue samples indicated that, at the time of death,~94% of the plutonium had accumulated in the systemic organs with 35% in the liver and 50% in the skeleton. About 9% of the total body activity was contributed by the remaining soft tissues. The 239, 240 Pu activity in the lungs and thoracic lymph nodes (~0.3% of the whole body activity) was negligible compared to the liver and skeleton. This is consistent with the assumption that the Registrant had no significant inhalation intakes throughout his employment. The ratio of 239, 240 Pu concentration in the lymph nodes to the concentration in the lungs was~1.6, indicating a minor exposure to airborne plutonium in a soluble form (32, 33) . The 239, 240 Pu intake and the resulting committed dose for this Registrant were evaluated using the combined set of available urine bioassay data and autopsy tissue analysis results. Since this individual was treated with Ca-DTPA during the first 6 months after the accident, only measurements of urine samples collected beyond 100 days after cessation of the chelation treatment were used in calculations.
Implementation of the NCRP 156 wound model (19) , coupled with the Leggett et al. plutonium systemic model (27) , using the maximum likelihood analysis method, resulted in a credible fit to the posttreatment urine data and predicted the plutonium retention in the liver and skeleton. Figure 3 compares the wound retention predicted by the NCRP model with the measured 239,240 Pu activities in the wound. The model predicted the measured wound retention reasonably well. However, the predicted wound activity at the time of death was a factor of three lower than the measured value. This result is consistent with the findings of a recent study on a PuO 2 contaminated wound, which used data from USTUR Case 0262 (18) . The authors of this study also showed that the default model parameters underestimated the plutonium retention in the wound and axillary lymph nodes. It is to be noted here that no data were available on the activity retained in the axillary lymph nodes of this individual to compare with the model predictions.
An attempt was made to derive a simple empirical fit to the wound retention data. The in vivo wound measurements and the post-mortem radiochemical analysis result (autopsy) were fitted with a single (17) resulted in a power function with the identical exponent value of −0.527 and r 2 = 0.980 ( Figure 4 ). This shows that plutonium activity in the wound decreases approximately as an inverse square root of time.
Based on maximum likelihood analysis, the fraction of the initial wound deposition not removed by chelation treatment was estimated as 288 Bq, with 78% strongly retained soluble material (nitrate) and 22% insoluble oxide particles. The corresponding committed effective dose was 134 mSv.
In order to examine the effectiveness of the chelation therapy and quantify the averted dose, the estimated residual intake (288.1 Bq) was combined with the activity excreted in urine during treatment (916 Bq). This resulted in an initial wound deposition of 1204 Bq. With the assumption of the same composition for the initially deposited material (78% soluble and 22% insoluble), the projected committed effective dose was calculated as 567 mSv. Hence, DTPA reduced the dose by a factor of 4.
CONCLUSIONS
The NCRP wound model (19) was applied to the urine bioassay and autopsy tissue analysis data from USTUR whole-body donation Case 0212, who had a major wound intake of plutonium, presumably, in a soluble form [Pu(NO 3 ) 4 ], and underwent extensive chelation treatment with i.v. injections of Ca-DTPA. For plutonium systemic biokinetics, the Leggett et al. model (27) was used. The maximum likelihood method was used to simultaneously fit the 'post-treatment' urinary excretion and post-mortem liver and skeleton retention data. The residual intake, the amount of plutonium deposited in the wound that was not removed from the system by Ca-DTPA, was estimated to be 288 Bq. It was demonstrated that the deposited material was predominantly a strongly retained soluble compound (nitrate) with a 22% fraction of plutonium particles (oxide).
By combining the estimated residual intake (288.1 Bq) with the plutonium activity excreted in urine during chelation treatment (916 Bq), a total wound deposition of 1204 Bq of 239 Pu was calculated. With the assumption that the initially deposited plutonium material was a mixture of soluble (nitrate) and insoluble (oxide) compounds, a projected untreated committed effective dose of 567 mSv was calculated and compared to the dose of 134 mSv that was actually received by the Registrant. In this case, Ca-DTPA treatment reduced the radiation dose by a factor of 4.
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